To date, no clear clinical evidence has been found to suggest the tumorigenic effect of GLP-1RAs (226), whereas plenty of studies have indicated that GLP-1RAs can inhibit the growth of ovarian, breast, prostate, and pancreatic cancer (227, 228)
Newer agents like retatrutide , which activates three receptors (GLP-1, GIP, and glucagon), and cagrilintide-semaglutide combinations may have different allodynia risk profiles that are not yet characterized
All the facilities and clinics with patients actively using Tirzepatide can find a non-identical dosage form that will keep prices low and margins high, or they can move their patients to a different drug that is still in short supply
At TrimRx, we are committed to providing the clinical expertise and modern technology needed to make this process as transparent and supportive as possible
Gde P, Lund-Andersen H, Parving H-H, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes